subscribeSubscribe
Salarius Provides Update on Review Process to Support Seclidemstat Trials

Salarius Provides Update on Review Process to Support Seclidemstat Trials
GLOBENEWSWIRE
22 Feb 2024
Share Share
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers
GLOBENEWSWIRE
03 Jan 2024
Share Share
Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program

Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program
GLOBENEWSWIRE
07 Nov 2023
Share Share
FDA frees Salarius’ rare cancer asset from clinical hold

FDA frees Salarius’ rare cancer asset from clinical hold
Gabrielle Masson FIERCE BIOTECH
10 May 2023
Share Share
Salarius to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer

Salarius to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer
GLOBENEWSWIRE
07 Mar 2023
Share Share
Investigators Present Data on Salarius’s Seclidemstat at ASH

Investigators Present Data on Salarius’s Seclidemstat at ASH
GLOBENEWSWIRE
13 Dec 2022
Share Share
Salarius Pharma Announces Interim Results from Phase 1/2 Trial of Seclidemstat

Salarius Pharma Announces Interim Results from Phase 1/2 Trial of Seclidemstat
GLOBENEWSWIRE
01 Dec 2022
Share Share
Salarius Announces Pause in Patient Enrollment in Ph1/2 Trial of Seclidemstat

Salarius Announces Pause in Patient Enrollment in Ph1/2 Trial of Seclidemstat
PRESS RELEASE
19 Oct 2022
Share Share
Salarius Adds 2 Mayo Clinic Sites to Ongoing Phase 1/2 Trial of Seclidemstat

Salarius Adds 2 Mayo Clinic Sites to Ongoing Phase 1/2 Trial of Seclidemstat
GLOBENEWSWIRE
22 Aug 2022
Share Share
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership

Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
GLOBENEWSWIRE
22 Sep 2021
Share Share